糖化产物在腹膜透析患者体内的变化及意义  

Observation of the glycation products in the patients on peritoneal dialysis

作　　者：肖洁[1] 程梅芬[2] 林善锬[2] 

机构地区：[1]广州医学院第一附属医院泌尿内科,广州510120 [2]上海医科大学华山医院肾内科,上海200040

出　　处：《中国血液净化》2003年第2期64-66,共3页Chinese Journal of Blood Purification

摘　　要：目的 探讨蛋白质非酶糖化的早期产物Amadori及糖化终末产物AGEs在非糖尿病尿毒症腹膜透析患者体内的浓度变化及与腹膜透析的相互影响。方法 用氯化硝基四氮唑蓝法测定早期糖化产物-果糖胺,用荧光分光光度计测定糖化终末产物(AGEs)。结果 腹膜透析(CAPD)组的果糖胺与AGEs均比正常组增高,差异有显著性。腹膜平衡试验(PET)组腹膜透析液各测定指标在0h,2h,4h各时间点两两比较均有显著差异(P<0.01)。结论 提示糖化产物在腹膜透析患者体内增多,腹膜透析清除效果差,且可能影响腹膜转运功能。Objective To investigate the changes of the early glycation products(fructosamine) and the advanced glycation end products(AGEs) in the patients on peritoneal dialysis.And to study the relationship between the glycation and peritoneal dialysis. Methods Levels of fructosamine was measured by nitroblue tetrazolium method. And levels of AGEs were measured by fluorescence method. Results Levels of patients on CAPD were significantly higher as compared with those in control subjects ( P < 0.01) . And levels of peritoneal dialysis fluid AGEs were different on 0h, 2h, 4h ( P <0.01). Conclusion It is shown that fructosamine and AGEs were significantly higher in patients on CAPD,and they could not be effectively removed by peritoneal dialysis.They could also reduce peritoneal transport effect.

关 键 词：糖化产物 腹膜透析 腹膜转运功能 蛋白质 非酶糖化 早期产物 终末产物 

分 类 号：R656.4[医药卫生—外科学]